Nuzenio

Tradingview Crispr Therapeutics

Tradingview Crispr Therapeutics entity intelligence is not indexable yet because Nuzenio needs more live source-attributed coverage.

topic 10 latest news signals 1 publisher sources 100/100 entity strength

Latest news

CRISPR Therapeutics' Q2 Earnings & Revenues Surpass Estimates - TradingViewTradingView · Tue, 04 Aug 2026 14:56:00 GMT CRISPR Therapeutics AG Stock 12‑Month Price Target Raised to $84.39, Implies 70% Upside - TradingViewTradingView · Tue, 04 Aug 2026 09:20:03 GMT CRSP Stock Climbs After-Hours As CRISPR Maps Busy Second-Half Pipeline After Upbeat Q2 - TradingViewTradingView · Mon, 03 Aug 2026 22:19:13 GMT CRISPR Therapeutics AG reports results for the quarter ended June 30 - Earnings Summary - TradingViewTradingView · Mon, 03 Aug 2026 21:38:37 GMT CRISPR Therapeutics reports Q2 2026: CASGEVY revenue $76M, net loss $91.2M, cash $2.36B - TradingViewTradingView · Mon, 03 Aug 2026 20:33:00 GMT CRSP: CASGEVY revenue soared and net loss narrowed in Q2 2026, with major clinical and regulatory advances - TradingViewTradingView · Mon, 03 Aug 2026 20:28:57 GMT Switzerland's CRISPR Therapeutics Q2 CASGEVY revenue jumps 151%, net loss narrows on FDA approval for expansion - TradingViewTradingView · Mon, 03 Aug 2026 20:26:45 GMT CRSP Q2'26 Earnings: revenue estimate is 7.45M USD - TradingViewTradingView · Mon, 03 Aug 2026 11:00:04 GMT

Timeline

Tue, 04 Aug 2026 14:56:00 GMTCRISPR Therapeutics' Q2 Earnings & Revenues Surpass Estimates - TradingView

Tue, 04 Aug 2026 09:20:03 GMTCRISPR Therapeutics AG Stock 12‑Month Price Target Raised to $84.39, Implies 70% Upside - TradingView

Mon, 03 Aug 2026 22:19:13 GMTCRSP Stock Climbs After-Hours As CRISPR Maps Busy Second-Half Pipeline After Upbeat Q2 - TradingView

Mon, 03 Aug 2026 21:38:37 GMTCRISPR Therapeutics AG reports results for the quarter ended June 30 - Earnings Summary - TradingView

Mon, 03 Aug 2026 20:33:00 GMTCRISPR Therapeutics reports Q2 2026: CASGEVY revenue $76M, net loss $91.2M, cash $2.36B - TradingView

Mon, 03 Aug 2026 20:28:57 GMTCRSP: CASGEVY revenue soared and net loss narrowed in Q2 2026, with major clinical and regulatory advances - TradingView

Related explainers

ElectionsElection stories need careful handling because polls, turnout, legal challenges, and campaign claims can change quickly.HealthHealth stories help readers understand public-health signals, medical research, hospital systems, medicines, disease updates, and safety guidance.HealthcareHealthcare stories can affect personal decisions, so Nuzenio treats them as information that should be checked with original sources and professionals.

Connected entities

TradingView TradingView6 live mentions CASGEVY6 live mentions CRISPR Therapeutics4 live mentions Earnings4 live mentions CRISPR Therapeutics AG4 live mentions Revenues Surpass Estimates2 live mentions Month Price Target2 live mentions Raised2 live mentions Implies2 live mentions Hours As CRISPR2 live mentions

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Tradingview Crispr Therapeutics.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

1 distinct publisher/source names are currently connected to this entity page.